Pentadeca Arginate

Pentadeca Arginate (PDA, also called BPC-157 Arginate Salt) is a stabilized salt form of the 15-amino-acid BPC-157 peptide sequence, with arginine added as a counter-ion for enhanced stability. The base peptide chain is identical to BPC-157 (Gly-Glu-Pro-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). The arginine salt form is proposed to improve oral and injectable bioavailability and stability compared with the acetate salt form of BPC-157. It emerged commercially after the September 2023 FDA Category 2 placement of BPC-157, positioned as a regulatory workaround.

The strategy is straightforward. BPC-157, as a "bulk drug substance," fell under FDA Section 503A compounding rules and was placed in Category 2 (cannot be compounded). PDA is positioned as a chemically distinct salt form that is not specifically named on the bulks list. The structural argument is that PDA represents a meaningfully different molecule. The skeptical interpretation is that the active peptide chain is identical to BPC-157 and the arginate modification is regulatory cosmetic.

The peptide chain is unchanged from BPC-157. The same 15 amino acids in the same sequence. The only difference is the counter-ion (arginine instead of acetate) that pairs with the peptide in the bulk drug form. Whether this constitutes a meaningfully different molecule for pharmacological or regulatory purposes is a contested question that has not been formally adjudicated.

The Evidence Base: Inherited Rather Than Earned

The PDA evidence base in 2026 is essentially inherited from BPC-157 rather than independently established.

Animal studies. No substantial body of animal studies has been published on PDA specifically. The animal literature available is the BPC-157 literature, with the assumption that PDA produces equivalent or improved effects. This assumption has not been validated.

Human trials. No published human trials of PDA specifically. The human evidence base is the same three small studies on BPC-157 (Lee and Padgett 2021 knee, Lee 2024 interstitial cystitis, Lee 2025 IV safety), none of which used PDA as the test compound.

Pharmacokinetic studies. Limited published data comparing PDA and BPC-157 pharmacokinetics in humans or animals. The stability and bioavailability claims rest on the chemistry argument rather than head-to-head pharmacokinetic trials.

Independent replication. Not available. The compound has not been the subject of independent academic research outside of vendor-affiliated publications and commentary.

This is the structural problem with PDA evidence. The compound is marketed as a superior version of BPC-157, but the published evidence does not include independent trials showing that superiority. The marketing rests on chemistry argument applied to inherited evidence from a related molecule, which is not the same as direct evidence for PDA itself.

For comparison, when liraglutide was followed by semaglutide, both compounds underwent independent Phase 3 trials in their own right. Semaglutide did not rely on liraglutide trial data as evidence of efficacy. The same standard has not been applied to PDA.

PDA's proposed mechanism is the same as BPC-157's. The peptide chain that drives biological activity is identical.

Pro-angiogenic activity. Upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) and increased blood vessel formation around injury sites. This is the most consistent finding in the BPC-157 animal literature and applies directly to PDA.

Nitric oxide system modulation. Context-dependent regulation of NO production, increased in ischemic settings and reduced in inflammatory ones. The mechanism documented for BPC-157 by Sikiric's group.

Growth factor pathway activation. Effects on FAK-paxillin complex, JAK-2, and ERK1/2 signaling supporting cell migration and adhesion.

Anti-inflammatory effects. Downregulation of NF-kB in injury settings.

The argument for PDA over BPC-157 typically focuses on pharmacokinetic stability rather than different molecular effects. Proponents claim:

• Improved oral bioavailability due to the arginate salt form
• Enhanced peptide stability during storage
• More consistent biological activity due to better solubility

These claims rest primarily on pharmacokinetic argument rather than independent comparative trials in animals or humans. The published comparative pharmacology data between PDA and BPC-157 is limited.

Regulatory status

The regulatory position of PDA is the central question for the compound's clinical use.

FDA Category 2 status. BPC-157 is on the Category 2 bulks list. Whether PDA falls under the same restriction depends on how the FDA interprets the relationship between the molecules. The peptide chain is identical. The salt form differs. FDA guidance on this question has not been definitively published, and the compounding industry has interpreted PDA as falling outside the explicit Category 2 listing for BPC-157.

PCAC meeting July 2026. The Pharmacy Compounding Advisory Committee will reconsider BPC-157 status at this meeting. The PDA question may be addressed directly or indirectly through the BPC-157 review. If the FDA explicitly extends Category 2 to PDA, the compounding workaround closes.

State pharmacy boards. Some state boards have provided guidance to compounding pharmacies about the regulatory status of PDA. The guidance varies. Some boards treat PDA as equivalent to BPC-157 and prohibit compounding. Others treat it as a distinct substance.

WADA status. PDA is not currently on the WADA Prohibited List as a specifically named substance. Whether it falls under the same prohibition as BPC-157 (section S0, non-approved substances) depends on athletic-governance interpretation. Athletes should treat PDA as effectively prohibited pending specific WADA guidance.

The compound has no FDA approval. There is no EMA, MHRA, or other major regulatory authorization. PDA is sold through compounding pharmacies that have interpreted the regulatory grey zone in their favor and through online research-chemical vendors.

Dosing protocols and literature-reported ranges are documented in the approved label or trial publications referenced above.

The PDA safety database is essentially the BPC-157 safety database. The BPC-157 animal literature has not flagged dose-limiting toxicity. The small human pilot studies have not reported serious adverse events. The FDA Category 2 designation cited insufficient safety data rather than documented harm.

Expected adverse events based on BPC-157 mechanism and limited clinical experience include:

Injection-site reactions. Mild local effects at subcutaneous injection sites.

Theoretical cancer concerns. The pro-angiogenic mechanism could theoretically support tumor vascularization in patients with active or recent malignancy. Not documented as a clinical signal but flagged in the 2025 Pharmaceuticals commentary on BPC-157 by Józwiak and colleagues.

Long-term safety unknown. No long-term randomized safety studies of PDA or BPC-157 have been completed in humans.

The arginate modification itself has not been associated with specific safety concerns beyond the parent peptide. Arginine is a common amino acid used in pharmaceutical formulations and has an established safety profile.

The major safety consideration with PDA is the same as with all unregulated peptide products: variable quality, identity, and purity from research-chemical and online compounding sources. Vials labeled "PDA" or "Pentadeca Arginate" have variable concentrations and stability across vendors.

For practical purposes, PDA and BPC-157 contain the same peptide chain. The differences are:

Counter-ion. PDA uses arginine; BPC-157 traditionally uses acetate. The counter-ion does not affect the receptor-binding pharmacology.

Pharmacokinetic claims. PDA is marketed as more stable, more orally bioavailable, and more biologically consistent. These claims rest on chemistry argument with limited direct comparative trial data.

Regulatory position. BPC-157 is explicitly on FDA Category 2; PDA's position is grey-zone.

Evidence base. BPC-157 has three small published human studies and an extensive animal literature. PDA has neither published human trials nor independent animal studies.

Cost. PDA is typically more expensive than BPC-157 (when both were available), reflecting the regulatory positioning and compounding-pharmacy markup.

For users prioritizing maximum available evidence, BPC-157 remains the molecule with more published human and animal data (limited as both are). For users prioritizing regulatory access in 2026, PDA may be available through some compounding pharmacies where BPC-157 cannot be legally produced.